Company data sheet · Takeda Pharmaceutical
Takeda Pharmaceutical: growth far beyond its economy.
- Industry
- Pharmaceutical Preparations Manufacturing
- Headquarters
- Japan
- Ticker
- TAK (NYSE)
- Sources
- SEC filings (2007–2026), Stratrix's verified Decision Cases, market data and official economic statistics for Japan
- Data as of
- October 18, 2026
- It outgrew its own economy many times over. Revenue rose from ¥1.73 trillion in fiscal 2017 to ¥4.58 trillion in fiscal 2025: 2.6 times as much. Japan's economy, counted the same way in money terms, grew about 15%. Whatever drove it, the economy around it does not account for growth of that size.
- Profitable every year. Takeda Pharmaceutical made money in each of its last nine fiscal years, from ¥44.2 billion (fiscal 2020) to ¥376 billion (fiscal 2021).
Financial results
| Fiscal year | Revenue | Net income | |
|---|---|---|---|
| 2017 | ¥1.73 trillion | ¥115 billion | |
| 2018 | ¥1.77 trillion | ¥187 billion | |
| 2019 | ¥2.10 trillion | ¥135 billion | |
| 2020 | ¥3.29 trillion | ¥44.2 billion | |
| 2021 | ¥3.20 trillion | ¥376 billion | |
| 2022 | ¥3.57 trillion | ¥230 billion | |
| 2023 | ¥4.03 trillion | ¥317 billion | |
| 2024 | ¥4.26 trillion | ¥144 billion | |
| 2025 | ¥4.58 trillion | ¥108 billion |
As reported in its annual filings, in JPY. Losses in red.
The full data sheet · Data Plan
Everything behind these findings, ready for your board deck.
- Economic context: 6 measures for Japan, every year since 2016, from the official sources.
- Peer comparison: against 264 companies of its size in its sector.
- Financial results: ten years of revenue, operating and net income, and every annual report, linked.
- Methods and sources, so each number can be checked and cited.
The full data sheet downloads with the Data Plan. To see exactly what you get first, open the Boeing sample PDF or Excel.